{"entity":{"type":"insider","cik":"0001610823","url":"/insider/0001610823","json_url":"/insider/0001610823.json","name":"Wiezorek Jeffrey","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":71,"n_filings":24,"first":"2015-05-19","last":"2017-09-27","span_basis":"filed_date"},"name_variants":[{"name":"Wiezorek Jeffrey","source":"filing","n_filings":24,"first_seen":"2015-05-19","last_seen":"2017-09-27"}],"transactions":[{"id":4907234,"accession":"0001209191-17-054197","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-054197","line_url":"/filing/0001209191-17-054197#line-2","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5283.0,"shares_display":"5,283","price_per_share":179.6639,"price_display":"179.66","price_state":"stated","total_value":949164.3837,"total_display":"949,164.38","total_whole":"949,164","shares_owned_after":25824.0,"shares_owned_after_display":"25,824","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-25","filed_date":"2017-09-27","scope":"insider"},{"id":4446835,"accession":"0001209191-17-044191","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-17-044191","line_url":"/filing/0001209191-17-044191","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":104.32005,"price_display":"104.32","price_state":"stated","total_value":1043200.5,"total_display":"1,043,200.50","total_whole":"1,043,201","shares_owned_after":22272.0,"shares_owned_after_display":"22,272","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-03","filed_date":"2017-07-06","scope":"insider","n_lines":2},{"id":4433960,"accession":"0000899243-17-005894","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-17-005894","line_url":"/filing/0000899243-17-005894","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18000.0,"shares_display":"18,000","price_per_share":75.00797388888888,"price_display":"75.01","price_state":"stated","total_value":1350143.53,"total_display":"1,350,143.53","total_whole":"1,350,144","shares_owned_after":21849.0,"shares_owned_after_display":"21,849","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-01","filed_date":"2017-03-02","scope":"insider","n_lines":8},{"id":4475635,"accession":"0001209191-17-008055","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-008055","line_url":"/filing/0001209191-17-008055#line-2","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":51.2134,"price_display":"51.21","price_state":"stated","total_value":76820.1,"total_display":"76,820.10","total_whole":"76,820","shares_owned_after":20695.0,"shares_owned_after_display":"20,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-01","filed_date":"2017-02-06","scope":"insider"},{"id":4827510,"accession":"0001209191-17-003225","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-003225","line_url":"/filing/0001209191-17-003225#line-2","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":75000.0,"total_display":"75,000.00","total_whole":"75,000","shares_owned_after":20695.0,"shares_owned_after_display":"20,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-06","filed_date":"2017-01-10","scope":"insider"},{"id":2603009,"accession":"0001209191-16-156552","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-156552","line_url":"/filing/0001209191-16-156552#line-1","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":716.0,"shares_display":"716","price_per_share":50.86,"price_display":"50.86","price_state":"stated","total_value":36415.76,"total_display":"36,415.76","total_whole":"36,416","shares_owned_after":15095.0,"shares_owned_after_display":"15,095","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-12-20","filed_date":"2016-12-22","scope":"insider"},{"id":2747397,"accession":"0001209191-16-153507","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-16-153507","line_url":"/filing/0001209191-16-153507","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Comon Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":50.7559,"price_display":"50.76","price_state":"stated","total_value":76133.85,"total_display":"76,133.85","total_whole":"76,134","shares_owned_after":15811.0,"shares_owned_after_display":"15,811","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-12-01","filed_date":"2016-12-05","scope":"insider","n_lines":2},{"id":2835061,"accession":"0001209191-16-149948","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-149948","line_url":"/filing/0001209191-16-149948#line-2","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":50.18,"price_display":"50.18","price_state":"stated","total_value":75270.0,"total_display":"75,270.00","total_whole":"75,270","shares_owned_after":15811.0,"shares_owned_after_display":"15,811","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-10","filed_date":"2016-11-14","scope":"insider"},{"id":3217084,"accession":"0001209191-16-145161","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-16-145161","line_url":"/filing/0001209191-16-145161","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":54.809533333333334,"price_display":"54.81","price_state":"stated","total_value":82214.3,"total_display":"82,214.30","total_whole":"82,214","shares_owned_after":15981.0,"shares_owned_after_display":"15,981","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-03","filed_date":"2016-10-05","scope":"insider","n_lines":2},{"id":2667931,"accession":"0001209191-16-139875","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-16-139875","line_url":"/filing/0001209191-16-139875","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":58.24161333333333,"price_display":"58.24","price_state":"stated","total_value":87362.42,"total_display":"87,362.42","total_whole":"87,362","shares_owned_after":16073.0,"shares_owned_after_display":"16,073","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-01","filed_date":"2016-09-02","scope":"insider","n_lines":2},{"id":3211668,"accession":"0001209191-16-135066","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-16-135066","line_url":"/filing/0001209191-16-135066","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":56.89548,"price_display":"56.90","price_state":"stated","total_value":85343.22,"total_display":"85,343.22","total_whole":"85,343","shares_owned_after":15476.0,"shares_owned_after_display":"15,476","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-01","filed_date":"2016-08-02","scope":"insider","n_lines":2},{"id":2666754,"accession":"0001209191-16-131280","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-131280","line_url":"/filing/0001209191-16-131280#line-2","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":50.0049,"price_display":"50.00","price_state":"stated","total_value":75007.35,"total_display":"75,007.35","total_whole":"75,007","shares_owned_after":14867.0,"shares_owned_after_display":"14,867","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-01","filed_date":"2016-07-05","scope":"insider"},{"id":3318775,"accession":"0001209191-16-125209","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-16-125209","line_url":"/filing/0001209191-16-125209","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":51.29933333333334,"price_display":"51.30","price_state":"stated","total_value":76949.0,"total_display":"76,949.00","total_whole":"76,949","shares_owned_after":15042.0,"shares_owned_after_display":"15,042","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-06-01","filed_date":"2016-06-02","scope":"insider","n_lines":2},{"id":3318764,"accession":"0001209191-16-125209","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-125209","line_url":"/filing/0001209191-16-125209#line-2","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":75000.0,"total_display":"75,000.00","total_whole":"75,000","shares_owned_after":14867.0,"shares_owned_after_display":"14,867","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-31","filed_date":"2016-06-02","scope":"insider"},{"id":2884427,"accession":"0001209191-16-109316","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-16-109316","line_url":"/filing/0001209191-16-109316","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9000.0,"shares_display":"9,000","price_per_share":44.88255,"price_display":"44.88","price_state":"stated","total_value":403942.95,"total_display":"403,942.95","total_whole":"403,943","shares_owned_after":17125.0,"shares_owned_after_display":"17,125","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-03-15","filed_date":"2016-03-17","scope":"insider","n_lines":4},{"id":3031607,"accession":"0001209191-16-100263","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-16-100263","line_url":"/filing/0001209191-16-100263","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9000.0,"shares_display":"9,000","price_per_share":44.07248444444444,"price_display":"44.07","price_state":"stated","total_value":396652.36,"total_display":"396,652.36","total_whole":"396,652","shares_owned_after":15130.0,"shares_owned_after_display":"15,130","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-02-16","filed_date":"2016-02-18","scope":"insider","n_lines":2},{"id":2354324,"accession":"0001209191-16-092247","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-16-092247","line_url":"/filing/0001209191-16-092247","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9000.0,"shares_display":"9,000","price_per_share":55.26432777777778,"price_display":"55.26","price_state":"stated","total_value":497378.95,"total_display":"497,378.95","total_whole":"497,379","shares_owned_after":15711.0,"shares_owned_after_display":"15,711","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-15","filed_date":"2016-01-19","scope":"insider","n_lines":6},{"id":8190777,"accession":"0001209191-15-085942","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-15-085942","line_url":"/filing/0001209191-15-085942","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9000.0,"shares_display":"9,000","price_per_share":63.77653333333333,"price_display":"63.78","price_state":"stated","total_value":573988.8,"total_display":"573,988.80","total_whole":"573,989","shares_owned_after":6833.0,"shares_owned_after_display":"6,833","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-15","filed_date":"2015-12-17","scope":"insider","n_lines":4},{"id":8813070,"accession":"0001209191-15-081113","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-15-081113","line_url":"/filing/0001209191-15-081113","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9000.0,"shares_display":"9,000","price_per_share":78.07562888888889,"price_display":"78.08","price_state":"stated","total_value":702680.66,"total_display":"702,680.66","total_whole":"702,681","shares_owned_after":7173.0,"shares_owned_after_display":"7,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-16","filed_date":"2015-11-18","scope":"insider","n_lines":5},{"id":8794030,"accession":"0001209191-15-076189","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-15-076189","line_url":"/filing/0001209191-15-076189#line-6","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4702.0,"shares_display":"4,702","price_per_share":62.54,"price_display":"62.54","price_state":"stated","total_value":294063.08,"total_display":"294,063.08","total_whole":"294,063","shares_owned_after":8814.0,"shares_owned_after_display":"8,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-10-15","filed_date":"2015-10-19","scope":"insider"},{"id":8794029,"accession":"0001209191-15-076189","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-15-076189","line_url":"/filing/0001209191-15-076189#line-5","is_derivative":false,"issuer_cik":"0001510580","issuer_name":"Kite Pharma, Inc.","issuer_ticker":"KITE","issuer_name_source":null,"issuer_url":"/issuer/0001510580","owner_cik":"0001610823","owner_name":"Wiezorek Jeffrey","owner_display_name":"Wiezorek Jeffrey","owner_url":"/insider/0001610823","role":"Officer (SVP Clinical Development)","role_mark":"O","role_mark_label":"Officer (SVP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2007.0,"shares_display":"2,007","price_per_share":63.5,"price_display":"63.50","price_state":"stated","total_value":127444.5,"total_display":"127,444.50","total_whole":"127,445","shares_owned_after":6807.0,"shares_owned_after_display":"6,807","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-10-15","filed_date":"2015-10-19","scope":"insider"}],"collapsed":true,"next_cursor":"2015-10-15|8794029","ledger_fault":false,"count":{"value":71,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":70,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":71},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001510580","name":"Kite Pharma, Inc.","url":"/issuer/0001510580","role":"Officer (SVP Clinical Development)","n_filings":24,"first_seen":"2015-05-19","last_seen":"2017-09-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001610823","retrieved_at":"2026-08-27T11:02:30+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}